Scarica l'app Stockscreener
6.99
6.30%
-0.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - TipRanks
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos reports progress on Phase 2 hepatitis B drug study By Investing.com - Investing.com Australia
Aligos Therapeutics stock rises on Phase 2 HBV study progress By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Investing News Network
ALGS Executive Vice President and Chief Medical Officer Resigns - GuruFocus
Aligos Therapeutics (ALGS) Updates on Phase 2 Study for Hepatitis B Treatment - GuruFocus
Aligos reports progress on Phase 2 hepatitis B drug study - Investing.com
Aligos Therapeutics provides phase 2 B-SUPREME study progress updates - marketscreener.com
Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates - marketscreener.com
ALGS: Piper Sandler to Host Virtual Meeting on January 22 - GuruFocus
Lobbying Update: $80,000 of ALIGOS THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
(ALGS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market - TipRanks
Aligos therapeutics appoints James Hassard as chief commercial officer By Investing.com - Investing.com Nigeria
Geopolitics Watch: Why retail investors favor Aligos Therapeutics Inc stockPrice Action & Risk Controlled Daily Plans - Bộ Nội Vụ
Why retail investors favor Aligos Therapeutics Inc. stockInflation Watch & Verified Swing Trading Watchlist - Bộ Nội Vụ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Investing News Network
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos therapeutics appoints James Hassard as chief commercial officer - Investing.com India
Aligos Therapeutics strengthens senior leadership team with the appointment of James Hassard as executive vice president, chief commercial officer - marketscreener.com
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Investing News Network
Why Aligos Therapeutics Inc. stock could be next big winnerJuly 2025 Recap & Accurate Entry and Exit Point Alerts - ulpravda.ru
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Strong-Buy" - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stock2025 Market Trends & Community Consensus Trade Signals - Улправда
How resilient is Aligos Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Why analysts remain bullish on Aligos Therapeutics Inc. stockJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
Trend Recap: Does Aligos Therapeutics Inc. stock trade at a discount to peers2025 Price Action Summary & Daily Stock Trend Watchlist - ulpravda.ru
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics - manilatimes.net
UBS Initiates Coverage of Aligos Therapeutics (ALGS) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on ALGS with a Buy Rating and $20 PT | AL - GuruFocus
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline - Investing.com
(ALGS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Is Aligos Therapeutics Inc a good long term investmentValue Traps to Avoid & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics Inc 5WK0 Stock Analysis and ForecastEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
Aug PreEarnings: How Aligos Therapeutics Inc 5WK0 stock reacts to fiscal policies2025 Pullback Review & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5%Time to Sell? - MarketBeat
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):